BofA/Merrill Lynch Upgrades Sagent Pharmaceuticals (SGNT) to Buy
Tweet Send to a Friend
BofA/Merrill Lynch upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Neutral to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
